Use of rituximab in three children with relapsed/refractory Burkitt lymphoma

Targeted Oncology

Volumn 5, Issue 4, 2010, Pages 291-294

  Akbayram, Sinan ^a   Doğan, Murat ^a   Akgün, Cihangir ^a   Erbey, Fatih ^b   Çaksen, Hüseyin ^a   Öner, Ahmet Faik ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b Van Maternity and Children's Hospital   (Turkey)

Author keywords

B cell non Hodgkin lymphoma; Burkitt lymphoma; Child; Rituximab

Indexed keywords

RITUXIMAB;

ABDOMINAL MASS; ADOLESCENT; ARTICLE; ASPIRATION BIOPSY; BLOOD CELL COUNT; BONE MARROW BIOPSY; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; INTENSIVE CARE; MALE; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 79952703618     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0161-6     Document Type: Article

References (25)

1. Dormann S, Duffner U, Martini C et al (2002) Brief report: chronic myelopathy after combined chemo-radiotherapy in a patient with relapsed mediastinal B-cell lymphoma. Med Pediatr Oncol 38:442-444 (Pubitemid 34507291)
2. Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin's lymphoma in childhood. N Engl J Med 334:1238-1248 (Pubitemid 126573365)
3. Griffin TC, Weitzman S, Weinstein H (2009) A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 52:177-181
4. Attias D, Weitzman S (2008) The efficacy of rituximab in highgrade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr 20:17-22
5. Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456-473
6. Shabbat S, Aharoni J, Sarid L et al (2009) Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma. Pediatr Blood Cancer 52:664-666
7. Manolopoulos L, Gomatos IP, Leandros E et al (2009) Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck. In Vivo 23:475-478
8. Bay A, Dogan M, Acikgoz M et al (2007) Rituximab in a child with relapsed Burkitt lymphoma. Pediatr Blood Cancer 49:218 (Pubitemid 47041119)
9. Corbacioglu S, Eber S, Gungor T et al (2003) Induction of longterm remission of a relapsed childhood B-ALL with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol/Oncol 25:327-329 (Pubitemid 36506223)
10. Vries MJ, Veerman AJ, Zwaan C (2004) Rituximab in three children with relapsed/refractory B-cell ALL/Burkitt NHL. Br J Haematol 125:405-417
11. Culic S, Culic V, Armanda V et al (2003) Anti-CD20 monoclonal antibody (rituximab) for therapy of mediastinal CD20 positive large B-cell NHL with a local tumor extension into lung of a 10- year-old girl. Pediatr Hematol Oncol 20:339-344 (Pubitemid 36648200)
12. Ozsahin H, Fluss J, McLin V et al (2002) Rituximab with IL-2 after autologous bone marrow transplantation for ALL in second remission. Med Pediatr Oncol 38:300-301 (Pubitemid 34258434)
13. Heath JA, Broxson EH, Dole MG et al (2002) EBV associated lymphoma in a child undergoing an autologous stem cell rescue. J Pediatr Hematol/Oncol 24:160-163 (Pubitemid 34150561)
14. Meinhardt A, Burkhardt B, Zimmermann M et al (2010) Berlin- Frankfurt-Münster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 28:3115-3121
15. Coiffier B, Haioun C, Ketterer N et al (1998) Rituximab (anti- CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927-1932 (Pubitemid 28446681)
16. Leget GA, Czuczman MS (1998) Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 10:548-551 (Pubitemid 28502249)
17. Song KW, Mollee P, Patterson B et al (2002) Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 119:125-127 (Pubitemid 35176510)
18. Quartier P, Brethon B, Philippet P et al (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511-1513 (Pubitemid 33055705)
19. Zecca M, Nobili B, Ramenghi U et al (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857-3861 (Pubitemid 36857857)
20. Scheinberg M, Hamerschlak N, Kutner JM et al (2006) Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 24:65-69
21. Giulino LB, Bussel JB, Neufeld EJ, Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network (2007) Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr 150:338-344
22. Vose JM, Link BK, Grossbard ML et al (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397 (Pubitemid 32112850)
23. Wilson WH, Gutierrez M, O'Connor P et al (2002) The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of doseadjusted EPOCH-R. Semin Oncol 29:41-47 (Pubitemid 34171794)
24. Winkler U, Schulz HR, Klein TO (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217-2224 (Pubitemid 29467667)
25. Stel AJ, ten Cate B, Jacobs S et al (2007) Fas receptor clustering and involvement of the death receptor pathway in rituximabmediated apoptosis with concomitant sensitization of lymphoma B cells to Fas-induced apoptosis. J Immunol 178:2287-2295